Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) price on Friday, August 27, rose 5.17% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $18.71.
A look at the stock’s price movement, the close in the last trading session was $17.79, moving within a range at $17.62 and $18.91. Turning to its 52-week performance, $23.57 and $2.40 were the 52-week high and 52-week low respectively. Overall, ORMP moved 28.33% over the past month.
Oramed Pharmaceuticals Inc.’s market cap currently stands at around $568.97 million. Analysts project the company’s earnings per share (EPS) to be -$0.19, which has seen fiscal year 2021 EPS growth forecast to increase to -$0.87 and about -$1.17 for fiscal year 2022. Per the data, EPS growth is expected to be -55.40% for 2021 and -34.50% for the next financial year.
Analysts have a consensus estimate of $1.25 million for the company’s revenue for the quarter, with a low and high estimate of $800k and $1.7 million respectively. The average forecast suggests up to a 83.60% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2021 to grow to $10.5 million, representing a 287.50% jump on that reported in the last financial year.
Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that ORMP is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.
4 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 4 recommend ORMP as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
ORMP’s current price about 10.30% and 26.11% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 60.04, while 7-day volatility ratio is 7.43% and 10.59% in the 30-day chart. Further, Oramed Pharmaceuticals Inc. (ORMP) has a beta value of 1.91, and an average true range (ATR) of 1.67. Analysts have given the company’s stock an average 52-week price target of $24.50, forecast between a low of $20.00 and high of $30.00. Looking at the price targets, the low is -6.89% off current price level while to achieve the yearly target high, price needs to move -60.34%. Nonetheless, investors will most likely welcome a -28.27% jump to $24.00 which is the analysts’ median price.
In the market, a comparison of Oramed Pharmaceuticals Inc. (ORMP) and its peers suggest the former has performed considerably stronger. Data shows ORMP’s intraday price has changed 5.17% in last session and 433.05% over the past year. Comparatively, Sanofi (SNY) has moved -0.02% on the day and only 2.11% in the past 12 months. Looking at another peer, we see that Novo Nordisk A/S (NVO) price has dipped -1.63% on the day. However, the stock is 53.76% off its price a year ago. Moreover, Ultragenyx Pharmaceutical Inc. (RARE) is also up 4.41% in trading on the day while keeping a an uptrend of 11.86% over the past year. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are up 0.88% and 0.69% respectively in the last trading.
If we refocus on Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), historical trading data shows that trading volumes averaged 0.94 million over the past 10 days and 782.22K over the past 3 months. The company’s latest data on shares outstanding shows there are 29.93 million shares.
The 2.50% of Oramed Pharmaceuticals Inc.’s shares are in the hands of company insiders while institutional holders own 17.70% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 2.39 million on Jun 29, 2021, giving us a short ratio of 3.78. The data shows that as of Jun 29, 2021 short interest in Oramed Pharmaceuticals Inc. (ORMP) stood at 7.70% of shares outstanding, with shares short falling to 2.48 million registered in May 27, 2021. Current price change has pushed the stock 341.27% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the ORMP stock continues to rise going into the next quarter.